News | March 02, 2026
Blue Jet Healthcare breaks ground on Rs. 2,300 crore pharma plant in Andhra Pradesh
The facility is expected to become operational by FY2028-29
The facility is expected to become operational by FY2028-29
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
The product addresses a market with approximately $66.8 million in annual sales as of December 2025.
Vinita has made expansion in the U.S. a core pillar of Lupin’s worldwide growth strategy
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
The approved product is a generic version of the reference listed drug (RLD) Lamictal ODT by GlaxoSmithKline and is indicated for the treatment of epilepsy and bipolar disorder
The new solution combines Watchmaker Genomics’ high-performance NGS chemistry with Volta’s digital fluidics platform
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
Subscribe To Our Newsletter & Stay Updated
